ANNOUNCEMENT

MedCity CONVERGE brings together the entire ecosystem to discuss Healthcare Innovation this July.

No short-term fixes for AstraZeneca, turnaround will take 3 to 4 years

No short-term fixes for AstraZeneca, turnaround will take 3 to 4 years

June 18, 2013 12:20 pm by | 0 Comments

LONDON (Reuters) - Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions set to take up to four years to pay ... Read more

After two deaths, FDA investigates Lilly schizophrenia drug

After two deaths, FDA investigates Lilly schizophrenia drug

June 18, 2013 10:29 am by | 0 Comments

(Reuters) - The U.S. Food and Drug Administration on Tuesday said it was investigating the deaths of two patients who died following injections with Eli Lilly and Co's long-acting treatment ... Read more


GSK in discussions to sell thrombosis drugs to Aspen in $1B deal

GSK in discussions to sell thrombosis drugs to Aspen in $1B deal

June 18, 2013 9:03 am by | 0 Comments

LONDON (Reuters) - GlaxoSmithKline is discussing the sale of its thrombosis drug brands Arixtra and Fraxiparine, along with a related French factory, to Aspen Pharmacare in a deal that could ... Read more

Cambridge site chosen for AstraZeneca’s global HQ, part of $2.3B restructuring plan

Cambridge site chosen for AstraZeneca’s global HQ, part of $2.3B restructuring plan

June 18, 2013 4:37 am by | 0 Comments

LONDON, June 18 (Reuters) - AstraZeneca has chosen a science park on the southern outskirts of Cambridge, England, next to the world-renowned Addenbrooke's Hospital, for its new $500 million global ... Read more

Success with an angel syndicate: How one pharma startup raised $16M without VCs

Success with an angel syndicate: How one pharma startup raised $16M without VCs

June 17, 2013 4:11 pm by | 0 Comments

This is the first of a two-part series on the evolution of angel investing. To read part two, click here.Savara Pharmaceuticals needed several million dollars to take its inhalable drug ... Read more

Money Map: Find a venture capital firm to fund your healthcare startup

Money Map: Find a venture capital firm to fund your healthcare startup

June 17, 2013 4:11 pm by | 0 Comments

Hard to understand, slow to exit and more than enough risk to go around.Not many investors are brave and smart enough to fund startups working to get new pharmaceuticals, medical ... Read more

ViroPharma isn’t looking, but sources say pharma companies are interested in bringing this orphan into their families

ViroPharma isn’t looking, but sources say pharma companies are interested in bringing this orphan into their families

June 17, 2013 11:29 am by | 0 Comments

NEW YORK (Reuters) - ViroPharma Inc is attracting preliminary interest from several pharmaceutical companies about buying the orphan drugmaker, according to three people familiar with the matter.While ViroPharma is not ... Read more


Supreme Court: FTC can challenge deals that keep cheaper generic drugs off market

Supreme Court: FTC can challenge deals that keep cheaper generic drugs off market

June 17, 2013 11:26 am by | 0 Comments

WASHINGTON (Reuters) - The U.S. Supreme Court ruled on Monday that the Federal Trade Commission can challenge deals that brand-name drug companies make with generic rivals to keep cheaper products ... Read more

J&J continues to build prostate cancer portfolio with $1B Aragon deal

J&J continues to build prostate cancer portfolio with $1B Aragon deal

June 17, 2013 8:16 am by | 0 Comments

(Reuters) - Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, bolstering J&J's role in the field after ... Read more

Roche’s Avastin approved in Japan for treatment of aggressive brain cancer

Roche’s Avastin approved in Japan for treatment of aggressive brain cancer

June 17, 2013 1:39 am by | 0 Comments

ZURICH (Reuters) - Japan's health ministry has approved drug Avastin for the treatment of aggressive brain cancer in Japan, Swiss pharmaceuticals company Roche said on Monday.Avastin is the first new ... Read more

New biotech company may prevent blood clots through its anticoagulant drug

New biotech company may prevent blood clots through its anticoagulant drug

June 16, 2013 7:04 pm by | 0 Comments

LONDON (Reuters) - British scientists have won early financial backing for a new kind of anticoagulant drug they believe may prevent dangerous blood clots without causing bleeding - a previously ... Read more

Teva’s Pfizer settlement triggers Moody’s downgrade

Teva’s Pfizer settlement triggers Moody’s downgrade

June 16, 2013 3:53 pm by | 0 Comments

On Friday, Moody's Investor Service reiterated its A3 rating for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), but lowered the outlook from "Stable" to "Negative", following the company's $1.6 ... Read more

Cognitive behavior therapy or drugs for patients with depression? A brain scan could tell

Cognitive behavior therapy or drugs for patients with depression? A brain scan could tell

June 14, 2013 5:51 pm by | 0 Comments

A biomarker could cut the trial-and-error of finding a patient's best therapy. A brain scan could one day help doctors prescribe the best treatment to patients with major depressive disorder. ... Read more

Controversial restless legs syndrome tied to men’s earlier deaths

Controversial restless legs syndrome tied to men’s earlier deaths

June 14, 2013 4:12 pm by | 0 Comments

NEW YORK (Reuters Health) - Men with restless legs syndrome (RLS) were more likely to die during an eight-year study than those without the condition, even after their age and ... Read more

Teva under investigation in Paris, six deaths may have resulted from packaging mistakes

Teva under investigation in Paris, six deaths may have resulted from packaging mistakes

June 14, 2013 12:00 pm by | 0 Comments

"Bloomberg" reports that Paris prosecutors have opened an investigation into drug packaging mistakes at a Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) plant in Sens, in north-central France, which ... Read more